INTRODUCTION AND OBJECTIVES: Variation in the utilization of Active Surveillance (AS) across urology practices has been described, but less is known about the degree of variation among urologists in the same practice. Furthermore, the relationship between the volume of low-risk patients a urologist manages (i.e., panel size) and his/her rate of AS utilization is not well described. In this context, we compared rates of AS utilization for men with low-risk prostate cancer (CaP) both within and across practices in Michigan to clarify whether efforts to decrease variation are best focused at practices or individual surgeons.
INTRODUCTION AND OBJECTIVES: Variation in the utilization of Active Surveillance (AS) across urology practices has been described, but less is known about the degree of variation among urologists in the same practice. Furthermore, the relationship between the volume of low-risk patients a urologist manages (i.e., panel size) and his/her rate of AS utilization is not well described. In this context, we compared rates of AS utilization for men with low-risk prostate cancer (CaP) both within and across practices in Michigan to clarify whether efforts to decrease variation are best focused at practices or individual surgeons.
METHODS: The Michigan Urological Surgery Improvement Collaborative (MUSIC) is a consortium of 43 diverse academic and community urology practices that maintains a prospective clinical registry for all patients diagnosed with CaP. From the registry, we identified all MUSIC practices with at least five urologists that each managed 5 men with newly-diagnosed low-risk CaP (i.e., clinical stage T2a, PSA <10 ng/mL, and biopsy Gleason score 6) from 1/2012 through 7/2016. We then examined the proportion of men undergoing initial AS across different practices and among surgeons within a given practice. Subsequently, a regression model was fit to determine whether a urologist 0 s rate of AS was correlated with individual panel size.
RESULTS: We identified 124 urologists from 13 practices that managed 2,646 men with low-risk CaP. The median practice and provider panel size was 166 (range 70-524) and 16 (range 5-141) patients, respectively. The proportion of men entering initial AS varied broadly across practices (range 30.6-72.9%; median 57.7%; p <0.001) (Figure) . In most practices, surgeon-specific use of initial AS also varied widely, with a maximum range of 0-100% in a practice with 38 urologists (Figure) . There was no significant relationship between a urologist 0 s panel size and his/ her rate of AS utilization (R 2 ¼ 0.01, p¼0.17). CONCLUSIONS: The proportion of patients entering initial AS varies widely across urology practices, among surgeons in the same practice, and is not correlated with a urologist 0 s panel size. These data suggest that interventions aimed at optimizing AS practice patterns must be tailored to individual surgeons rather than larger organizations regardless of patient volume.
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MP43-06 THE EFFECT OF TARGETED ANTIBIOTIC PROPHYLAXIS IN MEN UNDERGOING TRANSRECTAL ULTRASOUND GUIDED PROSTATE BIOPSY
Carling Cheung*, Hiten Patel, Patricia Landis, H. Ballentine Carter, Misop Han, Baltimore, MD INTRODUCTION AND OBJECTIVES: To investigate whether targeted antibiotic prophylaxis (TAP) using rectal swab cultures (RSC) prior to transrectal ultrasound guided prostate (TRUSP) biopsy has an effect on hospitalization for infectious complications related to TRUSP biopsies.
METHODS: We evaluated a cohort of men between 1995 and 2016 with prostate cancer on active surveillance (AS) receiving annual surveillance TRUSP biopsies. Routine RSC have been used to identify men with fluoroquinolone resistant (FQ-R) organisms since October 2012. Patients with FQ-R bacteria received TAP while patients without FQ-R bacteria received standard oral ciprofloxacin prophylaxis. We identified men with infectious complications requiring hospitalization for suspected post-biopsy sepsis via mailed questionnaires. The key questions identified patients hospitalized after a TRUSP biopsy for infection, and the date of admission. The incidence of infections requiring hospitalization was compared for patients receiving TAP vs. standard prophylaxis prior to TRUSP biopsy. The impact of FQ-R on hospitalization was assessed.
RESULTS: Of 1167 men currently on the AS program at our institution, 825 returned the questionnaire and were included in the analysis. For these men, there were a total of 3361 biopsy events. A total of 7 (0.79%) of 886 biopsies preceded by RSC resulted in infectious complications leading to hospitalization compared to 24 (0.97%) of 2475 biopsies without RSC (odds ratio (OR) 0.81 (0.35-1.89),p¼0.63). Among the 886 RSCs performed, FQ-R organisms were identified in 194 (21.9%). Six out of 194 (3.1%) biopsies with swabs positive for FQ-R organisms resulted in hospital admission while 1 out of 692 (0.14%) biopsies with swabs negative for FQ-R resulted in admission (OR 22.1 (2.6-184.3),p<0.01, Figure) . Age, race, and PSA at diagnosis did not significantly differ while smaller prostate volume at diagnosis was significantly associated with hospitalization (40.4 vs. 50.3 grams,p¼0.03).
CONCLUSIONS: Compared to empirical ciprofloxacin prophylaxis, TAP using RSC before undergoing TRUSP biopsy was associated with a nonsignificant decrease in rate of hospitalization for suspected post-biopsy sepsis. A RSC positive for FQ-R organisms and smaller prostate volume at diagnosis were associated with a higher rate of hospitalization.
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